about
The Structural Basis for the Prevention of Nonsteroidal Antiinflammatory Drug-Induced Gastrointestinal Tract Damage by the C-Lobe of Bovine Colostrum LactoferrinRole of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.The value of branded proton pump inhibitors: formulary considerations.Optimal treatment of laryngopharyngeal reflux disease.Pharmaceutical principles of acid inhibitors: unmet needs.Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end!The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment.Acta from the EndoFLIP® Symposium.Ilaprazole for the treatment of gastro-esophageal reflux.Vonoprazan fumarate for the management of acid-related diseases.Is the use of esomeprazole in gastroesophageal reflux disease a cost-effective option in Poland?Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppressionBravo capsule system optimizes intragastric pH monitoring over prolonged time: effects of ghrelin on gastric acid and hormone secretion in the rat.Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?Role of phospholipids in protection of the GI mucosa.Gastroprotective Mechanism and Ulcer Resolution Effect of Cyrtocarpa procera Methanolic Extract on Ethanol-Induced Gastric Injury.A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD).Treatment Challenges in the Management of Gastroparesis-Related GERD.Intravenous ilaprazole is more potent than oral ilaprazole against gastric lesions in rats
P2860
Q27646578-0A281594-4743-4F12-A4CB-6DFC0CB7DE2FQ30487910-414A37ED-1CE5-4757-84C9-399F1B9B986FQ35209935-75E21295-416B-49AB-A696-F64545A630ECQ37253915-D14B49E1-30E1-4A42-986C-42EAF0B57AD3Q37957701-F0752ED1-3E1E-446A-A82E-F2F1B56940CEQ38025449-C6CBB652-0367-41D5-825E-BB780A22BDC4Q38117182-AD3F0EF0-860F-4EFB-BDC3-BA16ECEA9CC0Q38174839-839215CF-726F-4AA6-89EC-68286CA50204Q38947217-D94D8A05-1175-4AE0-964B-41CA21C02F36Q39402205-7B7F693D-B5AE-4ED5-AF97-06BC765BDE9CQ39945028-84C54CD6-75A7-45A5-8C3B-BD9B7C5FEDE8Q42371575-65366C03-322B-42E1-B110-99F8F484A1F9Q42583281-80122943-E9B0-4099-A201-745C0C7606D0Q42923401-6AD7ECF5-31AF-4559-A3CB-67EB8D48BDE4Q43638429-ACD83F55-112C-45B4-83D8-9F74404601BCQ51744141-33140F1E-7C5C-403D-80A7-AD587BC552D0Q53731083-2E171AE9-C377-4DDF-A3B1-9524223DE219Q55533590-C6E7B4A1-9986-4C60-8604-91BF0E056ABFQ57222290-E1C6B7AF-0B9B-4BD0-95C5-21BF9A531698
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Acid suppression therapy: where do we go from here?
@ast
Acid suppression therapy: where do we go from here?
@en
type
label
Acid suppression therapy: where do we go from here?
@ast
Acid suppression therapy: where do we go from here?
@en
prefLabel
Acid suppression therapy: where do we go from here?
@ast
Acid suppression therapy: where do we go from here?
@en
P2093
P2860
P356
P1433
P1476
Acid suppression therapy: where do we go from here?
@en
P2093
Carmelo Scarpignato
Francesco Di Mario
Iva Pelosini
P2860
P356
10.1159/000091298
P577
2006-01-01T00:00:00Z